Pathogenic Germline Variants in 10,389 Adult CancersKuan‐lin Huang, Juok Cho, R. Jay Mashl et al.|Cell|2018Cited by 904
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N. Westin, Gordon B. Mills, Xiaoyan Ma et al.|Clinical Cancer Research|2021Cited by 76
Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancerShannon N. Westin, Gordon B. Mills, Marilyne Labrie et al.|medRxiv|2021Cited by 11
Abstract 2070: Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancersMarilyne Labrie, Shannon N. Westin, Zhenlin Ju et al.|Cancer Research|2019Cited by 3